SearchSearch results for: “”

Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b

Stibbe represented members of the Supervisory Board of the Dutch professional football club FC Twente when the club faced financial difficulties in 2016.

Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.

Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.

Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.

Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.

Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.

Advising FIFA on public law aspects of the Dutch and Belgian bid to organise the soccer World Championship

Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.